Epizyme (NASDAQ:EPZM) Now Covered by StockNews.com

StockNews.com began coverage on shares of Epizyme (NASDAQ:EPZMGet Rating) in a note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on EPZM. Cowen downgraded Epizyme from an “outperform” rating to a “market perform” rating and set a $1.50 price target on the stock. in a report on Monday, June 27th. HC Wainwright reduced their price target on Epizyme from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, June 3rd. Wedbush downgraded Epizyme from an “outperform” rating to a “neutral” rating in a report on Monday, June 27th. Finally, Cowen downgraded Epizyme from an “outperform” rating to a “market perform” rating and set a $1.50 target price on the stock. in a report on Monday, June 27th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Epizyme Stock Performance

EPZM opened at $1.47 on Friday. The company has a market cap of $247.44 million, a P/E ratio of -0.85 and a beta of -0.41. The business’s 50-day moving average price is $1.48 and its 200-day moving average price is $1.12. Epizyme has a 12 month low of $0.41 and a 12 month high of $5.80.

Epizyme (NASDAQ:EPZMGet Rating) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.15. Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 391.90%. The firm had revenue of $27.53 million for the quarter, compared to the consensus estimate of $10.11 million. Equities research analysts forecast that Epizyme will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Epizyme

A number of hedge funds have recently made changes to their positions in EPZM. Northern Trust Corp boosted its position in shares of Epizyme by 1.3% in the 4th quarter. Northern Trust Corp now owns 948,546 shares of the biopharmaceutical company’s stock worth $2,372,000 after purchasing an additional 12,285 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Epizyme by 69.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 63,127 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 25,876 shares in the last quarter. Bank of America Corp DE lifted its position in Epizyme by 6,665.3% in the 4th quarter. Bank of America Corp DE now owns 2,955,970 shares of the biopharmaceutical company’s stock valued at $7,390,000 after acquiring an additional 2,912,277 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Epizyme by 2,847.3% in the 4th quarter. BNP Paribas Arbitrage SA now owns 482,794 shares of the biopharmaceutical company’s stock valued at $1,207,000 after acquiring an additional 466,413 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Epizyme during the 4th quarter valued at $161,000. 76.45% of the stock is owned by institutional investors.

Epizyme Company Profile

(Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

See Also

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.